| Abstract | The pharmacokinetics of 2,000 mg of sulfadiazine administered twice daily (BID) versus those of 1,000 mg administered four times a day were compared in eight human immunodeficiency virus-infected patients. No differences in pharmacokinetic parameters were detected between the regimens. These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis. |
| Authors | M Kelli Jordan, Aaron H Burstein, Diane Rock-Kress, Raul M Alfaro, Alice K Pau, Joseph A Kovacs, Stephen C Piscitelli
(Affiliation: Pharmacy Department, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.)
|
| Journal | Antimicrobial agents and chemotherapy
(Antimicrob Agents Chemother)
Vol. 48
Issue 2
Pg. 635-7
(Feb 2004)
ISSN: 0066-4804 United States |
| PMID | 14742225
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
| Chemical References |
- Anti-Infective Agents
- Sulfadiazine
|
| Topics |
- Anti-Infective Agents
(administration & dosage, blood, pharmacokinetics)
- Area Under Curve
- Cross-Over Studies
- HIV Infections
(complications, metabolism)
- Half-Life
- Humans
- Models, Biological
- Sulfadiazine
(administration & dosage, blood, pharmacokinetics)
- Toxoplasmosis
(drug therapy, etiology)
|
